Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Advanced Research in Molecular Biology and Immunology of Gynecological Cancers
share announcement

Advanced Research in Molecular Biology and Immunology of Gynecological Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 4103

Special Issue Editors

Dr. Joanna Magdalena Gola

E-Mail Website
Guest Editor
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland
Interests: transcriptomics; micro-RNA; high-throughput techniques; natural compounds; drug toxicity; molecular markers; cancer; autoimmune diseases; personalized medicine
Dr. Barbara Strzałka-Mrozik

E-Mail Website
Guest Editor
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland
Interests: TGF signaling pathway; expression pattern; molecular markers; therapeutic targets; precision medicine; biological drugs; drug resistance; therapy monitoring
Dr. Aleksandra Mielczarek-Palacz

E-Mail Website
Guest Editor
Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland
Interests: immunology; diagnostic immunology; cancer; apoptosis; inflammation; cytokine

Special Issue Information

Dear Colleagues,

Gynecological cancers are complex diseases in which the mutual interaction between cancer cells and the surrounding normal cells is extremely important. The tumor microenvironment includes cells of the immune system which, by secreting cytokines, growth factors, and other immune mediators, can promote tumor growth and influence the effectiveness of the therapy. Despite the knowledge on the subject, many mechanisms still remain unclear.

The purpose of this Special Issue is to present advanced research into the molecular mechanisms underlying interactions between cancer and immune cells in gynecological cancers. We invite authors to submit original research articles and reviews that focus on interactions between cancer and immune cells in terms of molecular mechanisms. We also invite authors to contribute articles that present exclusively molecular research on gynecological cancers, as well as research solely on cancer immunology. This Special Issue will be devoted to research on molecular interaction networks, new biomarkers, therapeutic targets, innovative cancer therapy, as well as research on the anticancer activity of compounds, including compounds of natural origin and their derivatives. Articles concerning the molecular mechanisms of drug resistance and toxicity of anticancer compounds are also welcome.

Dr. Joanna Magdalena Gola
Dr. Barbara Strzałka-Mrozik
Dr. Aleksandra Mielczarek-Palacz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological cancer
  • biomarkers
  • genome analysis
  • RNA-seq
  • immunological mediators
  • molecular interaction networks
  • anticancer drug development
  • natural compounds
  • drug resistance
  • drug toxicity

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2360 KiB  
Article
Expression of E4 Protein and HPV Major Capsid Protein (L1) as A Novel Combination in Squamous Intraepithelial Lesions
by Marcin Przybylski, Dominik Pruski, Sonja Millert-Kalińska, Monika Krzyżaniak, Mateusz de Mezer, Magdalena Frydrychowicz, Robert Jach and Jakub Żurawski
Biomedicines 2023, 11(1), 225; https://doi.org/10.3390/biomedicines11010225 - 16 Jan 2023
Cited by 1 | Viewed by 2050
Abstract
We aim to describe the relationship between the immunohistochemical expression patterns of HPV E4 markers and the presence of HPV major capsid protein (L1) in cervical tissues obtained by biopsy of patients with abnormal liquid-based cytology (LBC) results, HR HPV infections, or clinically [...] Read more.
We aim to describe the relationship between the immunohistochemical expression patterns of HPV E4 markers and the presence of HPV major capsid protein (L1) in cervical tissues obtained by biopsy of patients with abnormal liquid-based cytology (LBC) results, HR HPV infections, or clinically suspicious cervix. A novel HPV-encoded marker, SILgrade-E4 (XR-E4-1), and an HPV (clone K1H8) antibody were used to demonstrate the expression in terminally differentiated epithelial cells with a productive HPV infection in the material. A semiquantitative analysis was performed based on light microscope images. The level of E4 protein decreased with the disease severity. Patients with LSIL-CIN 1 and HSIL-CIN 2 diagnoses had significantly lower levels of HPV major capsid protein (L1) than those without confirmed cervical lesions. Our analysis confirms a higher incidence of L1 in patients with molecularly diagnosed HPV infections and excluded lesions of LSIL-CIN 1 and HSIL-CIN 2. Further studies on the novel biomarkers might help assess the chances of the remission of lesions such as LSIL-CIN 1 and HSIL-CIN 2. Higher levels of E4 protein and L1 may confirm a greater probability of the remission of lesions and incidental infections. In the cytological verification or HPV-dependent screening model, testing for E4 protein and L1 expression may indicate a group with a lower risk of progression of histopathologically diagnosed lesions. Full article
(This article belongs to the Special Issue Advanced Research in Molecular Biology and Immunology of Gynecological Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 380 KiB  
Review
MicroRNAs as Potential Biomarkers in Gynecological Cancers
by Joanna Miśkiewicz, Aleksandra Mielczarek-Palacz and Joanna Magdalena Gola
Biomedicines 2023, 11(6), 1704; https://doi.org/10.3390/biomedicines11061704 - 13 Jun 2023
Cited by 1 | Viewed by 1439
Abstract
MicroRNAs are non-coding transcripts that, thanks to the ability to regulate the mRNA of target genes, can affect the expression of genes encoding tumor suppressors and oncogenes. They can control many important cellular processes, including apoptosis, differentiation, growth, division, and metabolism. Therefore, miRNAs [...] Read more.
MicroRNAs are non-coding transcripts that, thanks to the ability to regulate the mRNA of target genes, can affect the expression of genes encoding tumor suppressors and oncogenes. They can control many important cellular processes, including apoptosis, differentiation, growth, division, and metabolism. Therefore, miRNAs play an important role in the development of many cancers, including gynecological cancers. Ovarian cancer, endometrial cancer, cervical cancer, and vulvar cancer are the most common cancers in women and are a frequent cause of death. The heterogeneity of the pathogenesis of these gynecological diseases makes the diagnostic process a significant obstacle for modern medicine. To date, many studies have been carried out, in which particular attention has been paid to the molecular pathomechanism of these diseases, with particular emphasis on miRNAs. To date, the changed profile of many miRNAs, which influenced the promotion of proliferation, migration, invasion processes and the simultaneous inhibition of programmed cell death, has been proven many times. Detailed understanding of the molecular effects of miRNAs in the above-mentioned gynecological cancers will enable the development of potential predictive and prognostic biomarkers, as well as the optimization of the diagnostic process. Full article
(This article belongs to the Special Issue Advanced Research in Molecular Biology and Immunology of Gynecological Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop